Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Accuracy of Laboratory Assays in Ophthalmic Practice—Reply

Accuracy of Laboratory Assays in Ophthalmic Practice—Reply Letters Published Online: October 29, 2015. doi:10.1001/jamaophthalmol.2015.4100. leagues, recognizing that between-subject variability affects Conflict of Interest Disclosures: All authors have completed and submitted the diagnostic capacity. ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Ehlers reported The TearLab system is described as a “laboratory-on-a- receiving personal fees from Bioptigen, Thrombogenics, Zeiss, Alcon, and Leica; chip” assay that facilitates rapid, clinical implementation of a receiving a grant from Thrombogenics; having a patent pending and a patent diagnostic test compared with a laboratory-based assay. Con- licensed for a microscope mount for a portable OCT system with royalties paid to Bioptigen; having a patent pending and a patent licensed to Synergetics for sideration regarding the potential influence of exogenous fac- OCT-compatible instrumentation; having a patent pending for pathology- tors on the reliability of the assay is essential. specific OCT software; and having a patent pending for a surgeon feedback As the TearLab system uses temperature-corrected imped- system for intraoperative OCT. No other disclosures were reported. ance to measure osmolarity, measurement outcomes may be in- Funding/Support: Dr Ehlers was supported by grant K23-EY022947-01A1 from fluenced by variations in room temperature. Our evaluation has the National Eye Institute, grant TECH-13-059 from the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Ophthalmology American Medical Association

Accuracy of Laboratory Assays in Ophthalmic Practice—Reply

Loading next page...
 
/lp/american-medical-association/accuracy-of-laboratory-assays-in-ophthalmic-practice-reply-w0ka5alb0J
Publisher
American Medical Association
Copyright
Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6165
eISSN
2168-6173
DOI
10.1001/jamaophthalmol.2015.3858
pmid
26468635
Publisher site
See Article on Publisher Site

Abstract

Letters Published Online: October 29, 2015. doi:10.1001/jamaophthalmol.2015.4100. leagues, recognizing that between-subject variability affects Conflict of Interest Disclosures: All authors have completed and submitted the diagnostic capacity. ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Ehlers reported The TearLab system is described as a “laboratory-on-a- receiving personal fees from Bioptigen, Thrombogenics, Zeiss, Alcon, and Leica; chip” assay that facilitates rapid, clinical implementation of a receiving a grant from Thrombogenics; having a patent pending and a patent diagnostic test compared with a laboratory-based assay. Con- licensed for a microscope mount for a portable OCT system with royalties paid to Bioptigen; having a patent pending and a patent licensed to Synergetics for sideration regarding the potential influence of exogenous fac- OCT-compatible instrumentation; having a patent pending for pathology- tors on the reliability of the assay is essential. specific OCT software; and having a patent pending for a surgeon feedback As the TearLab system uses temperature-corrected imped- system for intraoperative OCT. No other disclosures were reported. ance to measure osmolarity, measurement outcomes may be in- Funding/Support: Dr Ehlers was supported by grant K23-EY022947-01A1 from fluenced by variations in room temperature. Our evaluation has the National Eye Institute, grant TECH-13-059 from the

Journal

JAMA OphthalmologyAmerican Medical Association

Published: Dec 1, 2015

References